FMT and ulcerative colitis: Oral treatment shown to be a ‘promising and feasible’ approach – Lancet study

By Tingmin Koe contact

- Last updated on GMT

Oral faecal microbiota transplantation (FMT) has shown to be effective in treating patients suffering from active ulcerative colitis. ©Getty Images
Oral faecal microbiota transplantation (FMT) has shown to be effective in treating patients suffering from active ulcerative colitis. ©Getty Images

Related tags: FMT, Ulcerative colitis, Lancet

A 56-week long clinical trial using orally administered faecal microbiota transplantation (FMT) has led to remission in patients suffering from active ulcerative colitis.

The double-blind, randomised, placebo-controlled trial was conducted at Concord Repatriation General Hospital and St Vincent’s Hospital in Australia between 2019 and 2020.

Findings of the study were published in Lancet Gastroenterology and Hepatology.

Thirty-five patients with ulcerative colitis for more than three months were involved in the trial. They were between the age of 18 and 75 years old.

After two weeks of antibiotic treatment consisting of amoxicillin, metronidazole, and doxycycline, the patients were randomly assigned to receive either oral lyophilised FMT or placebo capsules for eight weeks.

The oral FMT was prepared from two healthy unrelated donors without gastrointestinal symptoms or recent use of antibiotics and probiotics.

The researchers also conducted 16S rRNA amplicon sequencing on the donors’ FMT samples to exclude the presence of Sutterella ​and Fusobacterium ​species.

At week eight, 10 patients in the FMT group who achieved positive response – meaning a corticosteroid-free clinical or endoscopic response – were randomly assigned to either continue or to withdraw FMT for another 48 weeks.

“To the best of our knowledge, our randomised, double-blind, placebo-controlled study of oral FMT in ulcerative colitis is the first clinical trial using an intensive, exclusively oral regimen of FMT in the induction of remission of ulcerative colitis,” ​said the researchers.

Findings

At week eight, 53 per cent of the patients in the FMT group were in corticosteroid-free clinical remission with endoscopic remission.

In contrast, only 15 per cent of those in the placebo group were in remission.

In patients who were recruited to continue the study for another 48 weeks, it was found that those who continued FMT were in clinical, endoscopic, and histologic remission by the end of the study. 

However, no remission in active ulcerative colitis was seen in those who were given the placebo during the 48 weeks. 

“Antibiotics followed by orally administered FMT was associated with the induction of remission in patients with active ulcerative colitis.

“Continuing FMT was well tolerated and appeared to demonstrate clinical, endoscopic, and histological efficacy. Oral FMT could be a promising and feasible treatment option for patients with ulcerative colitis.”

Bacteria diversity

Oral FMT was shown to increase the bacteria species richness, as compared to the placebo treatment.

For example, there was a significant increase in donors’ bacteria species in patients receiving FMT.

In addition, in patients who responded positively to the FMT treatment, Bacteroides ​OTU19 was found to have uniquely increased, while non-responders showed an increase in Bacteroides ​OTU14.

In patients from the placebo group but achieved clinical and endoscopic recovery, a linear, rather than exponential post-antibiotic recovery of bacterial species richness was seen.

Donors’ roles

The donors also played an important role on the outcome of the trial.

Between the two donors, one of the donors had a significantly higher bacterial diversity, driven by higher species evenness rather than richness.

All patients who took oral FMT from this particular donor reported corticosteroid-free clinical remission and either endoscopic remission or response.

However, only 36 per cent of the patients who took oral FMT from the other donor reported a positive response to the treatment.

Adverse events  

Adverse events were reported in 67 per cent and 85 per cent of the patients in the FMT and placebo group respectively.

The adverse events were generally mild and self-limiting gastrointestinal complaints.

However, serious adverse events were also reported, including worsening ulcerative colitis in two patients from the FMT group, one in the placebo group, and per-rectal bleeding in one of the patients from the placebo group.

Find out more about the trial and the potential of oral FMT here. 

 

Source: Lancet Gastroenterology and Hepatology

Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial

https://doi.org/10.1016/S2468-1253(21)00400-3

Author: Rupert Leong et al

Related news

Show more

Related products

show more

KaraLiv™ Helps Improve Liver Health in 30 Days

KaraLiv™ Helps Improve Liver Health in 30 Days

Karallief® Inc | 25-May-2022 | Data Sheet

KaraLiv™ is a patent-pending and clinically tested vegan herbal blend that promotes liver function in 30 days. After extensive R&D and exploration...

Follow us

Products

View more

Webinars

Nutra Champions Podcast

Nutra Champions Podcast